Bavarian Nordic (OTCMKTS:BVNRY) Sees Significant Growth in Short Interest

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 1,506 shares, a growth of 137.9% from the August 15th total of 633 shares. Based on an average daily trading volume, of 12,092 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Bavarian Nordic Price Performance

Shares of BVNRY opened at $10.51 on Monday. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $13.00. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of 10.61 and a beta of 1.20. The business has a 50-day moving average of $9.86 and a 200-day moving average of $9.78.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its earnings results on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a return on equity of 12.06% and a net margin of 24.36%.

Bavarian Nordic Company Profile

Bavarian Nordic A/S (OTCMKTS:BVNRY) is a Danish biotechnology company that develops, manufactures and commercializes vaccines for infectious diseases. The company serves government agencies, military organizations, healthcare providers and travelers, with products distributed across Europe, North America and other international markets.

Its best-known product is JYNNEOS, also marketed as IMVAMUNE or IMVANEX in certain regions, a non-replicating smallpox and mpox vaccine. Bavarian Nordic also offers vaccines for rabies and tick-borne encephalitis, including RabAvert and Rabipur for rabies prevention and Encepur for protection against tick-borne encephalitis.